普伐他汀对成功冠脉成形术患者的影响

Effects of Pravastatin on Patients with Successful Percutenous Transluminal Coronary Angioplasty

为探讨普伐他汀对成功冠脉成形术患者术后６月再狭窄发生率及心脏事件的影响，将４８例患者（男３８例，女１０例，年龄６０．４ ± ７．９岁）随机从手术当晚起口服普伐他汀（每日 １０ｍｇ）或安慰剂，随访平均 ６月，观察心脏事件，随访结束时复查冠脉造影和血脂。结果显示术后６个月时普伐他汀组血脂参数明显改善，以总胆固醇和低密度脂蛋白胆固醇下降最为明显（分别为 １１．４％和 １４．４％， Ｐ＜０．０１）。冠脉造影显示，两组再狭窄发生率无明显差异（４０．９％对３８．５％，Ｐ＞０．０５）。心脏事件发生率普伐他汀组明显低于对照组（１１．５％对３６．４％， Ｐ＜０．０１），普伐他汀药物不良反应少。本组结果显示普伐他汀可以减少术后６个月内心脏事件的发生。

The effects of pravastatin on coronary restenosis and cardiac events were studied in 48 patients with successful percutenous transluminal coronary angioplasty. The patients were randomized into pravastatin (n=26) and control (n=22) groups. Pravastatin (10mg daily) or placebo were administered from the night of angioplasty day. The patients were followed up for mean 6 months. Coronary angiopraphy was repeated at the end of follow up period. It was showed that plasma lipid parameters were improved significantly as compared with those of pretreatment, especially total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) (decreased by 11 .4% and 14.4%, respectively, p<0.01 ). There was no difference in the incidence of coronary restenosis between both groups (40.9% vs 38.5%, P>0.05%). The incidence of cardiac events was lower in pravastatin group than in the control group (11 .5% vs 36.4%, p<0.01). The adverse reactions of pravsatatin were mild. The results suggest that pravsatatin decreases the occurrence of cardiac events though it dose not reduce the incidence of coronary restenosis.